ArticleExperimental & molecular medicine2026
4E-BP1 acts as a molecular rheostat balancing regenerative healing and fibrotic scarring.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Efficient wound healing relies on tightly coordinated protein synthesis to support the complex cellular activities underlying tissue repair. However, the mechanisms governing translational control during tissue regeneration remain incompletely defined. Here, we identify the mTORC1 effector 4E-binding protein 1 (4E-BP1) as a critical regulator of wound repair and fibrotic remodeling. Phosphorylated 4E-BP1 was markedly increased in wounds and fibrotic tissues, indicating dynamic engagement of the mTORC1/4E-BP1 signaling axis during repair. Functional studies revealed that genetic ablation of 4E-BP1, mimicking fully phosphorylated 4E-BP1, enhanced re-epithelialization, angiogenesis, and granulation tissue formation in wound tissues, yet concurrently promoted myofibroblast activation and excessive collagen deposition, and fibrotic progression in bleomycin-induced skin fibrosis. Conversely, sustained overexpression of 4E-BP1 impaired wound closure and attenuated fibrotic responses. Moreover, in vitro, 4E-BP1 expression directly governed transforming growth factor-β1-mediated fibroblast collagen synthesis. Phosphorylated 4E-BP1 levels and related transcriptional signatures were elevated in human skin fibrotic scar tissues. These findings demonstrate that 4E-BP1 acts as an mTORC1-downstream effector that shapes the balance between reparative efficiency and fibrotic remodeling. Targeting the mTORC1/4E-BP1 signaling axis may therefore offer novel therapeutic opportunities to optimize wound healing and prevent pathological scarring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.